Nov, 22: Pfizer Inc (PFE.N) announced on Monday that, its COVID-19 vaccine showed strong long-term protection against the virus in a late-stage study performed among adolescents aged 12 to 15 years. Pfizer and BioNTech will seek approval for a 30 micrograms dose of the vaccine for those aged 12 and above.
